New Delhi, July 3 -- Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by bacterial antimicrobial resistance in India, a growing health crisis.

The company, a leader in the infectious diseases segment, has already launched two antibiotics targetting such superbugs, and sees the segment as a long-term focus area, a senior executive told Mint.

"Since we began our work on (antimicrobial drug resistance), our strategic plan has been to introduce three to four products in the AMR space over a 5-year horizon," Dr. Jaideep Gogtay, Cipla's global chief medical officer, said in an interview.

"I think it will be a long-term strategy. As a company which remains focused on India, the...